drugset / Trial / NCT04589754
Adriamycin and Ifosfamide Combined With Sintilimab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study was to explore the efficacy and safety of adriamycin and ifosfamide combined with sintilimab versus chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma.
Timeline
- Start
- 2021-07-26
- Primary completion
- 2025-12-30
- Completion
- 2026-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 100 mg | Intravenous |
| Background | CTX | Unknown | 1.2 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Ifosfamide | Small molecule | 1.5 g | Intravenous |
| Background | Ifosfamide | Small molecule | 2.5 g | Intravenous |
| Background | VCR | Unknown | 1.4 mg/m2 | Intravenous |